Order Article Reprints

Kim J, Park KE, Jeong Y-S, Kim Y, Park H, Nam J-H, Jung K, Son WS, Jung HS, Lee J-H, et al. Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer. Cancers. 2020; 12(6):1575. https://doi.org/10.3390/cancers12061575

Kim, Jooseok, Kyung Eui Park, Yoo-Seong Jeong, YeongMun Kim, Hayeon Park, Ji-Hye Nam, Kyungsoo Jung, Woo Sung Son, Hun Soon Jung, Jong-Hwa Lee, and et al. 2020. "Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer" Cancers 12, no. 6: 1575. https://doi.org/10.3390/cancers12061575

Kim, J., Park, K. E., Jeong, Y.-S., Kim, Y., Park, H., Nam, J.-H., Jung, K., Son, W. S., Jung, H. S., Lee, J.-H., Jeong, S. H., Kim, N. A., Ha, J. D., Cho, S. Y., Choi, Y.-L., Chung, S.-J., Choi, J. Y., Hong, S., & Shin, Y. K. (2020). Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer. Cancers, 12(6), 1575. https://doi.org/10.3390/cancers12061575